- Report
- October 2024
- 193 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- September 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- August 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Clinical Trials
- July 2024
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- September 2018
- 174 Pages
Global
From €1251EUR$1,375USD£1,073GBP
€2503EUR$2,750USD£2,146GBP
- Report
- March 2024
- 397 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- April 2024
- 160 Pages
Global
From €4522EUR$4,969USD£3,877GBP
- Report
- April 2018
- 26 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Report
- March 2018
- 20 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Report
- January 2025
- 90 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Risperdal is a medication used to treat mental disorders such as schizophrenia, bipolar disorder, and irritability associated with autism. It is an atypical antipsychotic drug, meaning it works differently than traditional antipsychotics. Risperdal works by blocking certain receptors in the brain that are associated with psychotic symptoms. It is also used to treat symptoms of depression and anxiety.
Risperdal is one of the most commonly prescribed medications for mental disorders. It is available in both oral and injectable forms, and is often used in combination with other medications. It is generally well-tolerated, but can cause side effects such as weight gain, drowsiness, and dry mouth.
The Risperdal market is highly competitive, with many companies offering similar products. Some of the major players in the market include Johnson & Johnson, Pfizer, Novartis, and Eli Lilly. Other companies include AstraZeneca, Teva Pharmaceuticals, and Mylan. Show Less Read more